Fibrinolytic therapy, also termed thrombolytic therapy, is a medical strategy designed to dissolve blood clots within the vascular system. The formation of blood clots, or thrombi, poses significant health threats by obstructing blood vessels and giving rise to conditions like pulmonary embolism or deep vein thrombosis. Utilizing fibrinolytic agents, such as tissue plasminogen activator (tPA), this intervention facilitates the breakdown of fibrin, a key protein in blood clot formation. The administration of fibrinolytic therapy is particularly time-critical, especially in acute scenarios such as pulmonary embolism, where prompt action can prevent or mitigate severe consequences. Despite its effectiveness, fibrinolytic therapy is not without risks, with potential complications including bleeding. Consequently, its application is judiciously weighed against individual patient factors and the specific clinical context. As medical research advances, ongoing exploration seeks to refine approaches, aiming to improve the safety and efficacy of fibrinolytic therapy, contributing to the continual enhancement of vascular care.